Eevia Health (EEVIA) Status Update summary

Strategic focus and market positioning

• Shifted strategy from generic, compendial extracts to condition-specific, branded nutraceutical ingredients with clinical substantiation, focusing on gut and digestive health as a primary growth area.

• Targeting gut health market, valued over $40 billion and growing, with unique polyphenol-based solutions distinct from common probiotic approaches.

• Building partnerships with leading scientific experts and leveraging a global distribution network to introduce new products, starting with practitioner channels and expanding to mainstream brands.

Operational and financial restructuring

• Implementing aggressive cost-cutting, divestment of non-core assets, and streamlining operations to restore revenue growth and profitability.

• Divesting the eye health product Retinari and wood-based business to focus resources on core proprietary products, with external funding sought for divested units.

• Relocating standard extract production to Lapland for cost advantages, automation, and access to funding, aiming to match or beat Asian competitors on cost.

Financial outlook and funding

• Revenue declined sharply in 2024 after a key customer stopped ordering, but positive EBITDA was achieved in 2023 due to improved gross margins.

• 2025 targets include €3 million in revenue and a return to positive EBITDA, with a goal to quadruple revenues in the near future.

• Liquidity to be improved through a rights issue, inventory reduction, and proceeds from divestments; debt-to-equity swap included in the equity issue.